Across therapy areas, GoodRx’s POS rebates improve access and affordability for cash-paying patients

Across therapy areas, GoodRx Assist is a proven point-of-sale rebate program for cash-paying patients.

March 13, 2023

IQVIA’s OG of data analytics on the latest clinical trial trends

IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

By Taren Grom • March 10, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

Reata’s stock plummets amid sudden FDA neuro office shakeup

The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

By Karissa Waddick • Feb. 28, 2023

Multimillion-dollar therapies are changing how payers foot the bill

With more gene therapies headed to market, novel payment methods are emerging from regulators and academia. 

By Meagan Parrish • Feb. 28, 2023

Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023

Managing for resilience: Passage’s ups and downs in gene therapy

After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

By Meagan Parrish • Feb. 15, 2023

For Complement’s CEO, storytelling could be just as critical as data

Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.

By Alexandra Pecci • Feb. 14, 2023

Why are there gaps in mental healthcare? Often it’s flawed trial methodology

Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.

By Kelly Bilodeau • Feb. 10, 2023

United by inequity: The healthcare disparities plaguing rare disease patients and Black Americans

Guided by her personal experiences, Tamar Thompson is aiming to improve rare disease care through her advocacy work at Alexion, AstraZeneca Rare Disease.

By Alexandra Pecci • Feb. 7, 2023

Woman of the Week: Bayer’s Dr. Yesmean Wahdan

The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

By Taren Grom • Feb. 1, 2023

Patients are using social media — clinical trial experts can learn from that

Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights. 

By Karissa Waddick • Jan. 30, 2023

A biotech CEO’s favorite ‘F’ word

At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

By Taren Grom • Jan. 26, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Woman of the Week: Dr. Lauren Lazar

As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

By Taren Grom • Jan. 25, 2023

Pro sports’ COVID protocols led to real-world data impacts for pharma

After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

By Karissa Waddick • Jan. 16, 2023

How biotechs can weather the market storm

Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

By Meagan Parrish • Jan. 13, 2023

A new mission in menopause — extending the lives of women

Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.

By Meagan Parrish • Jan. 5, 2023

Nonprofits are bridging R&D’s valley of death

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

By Kelly Bilodeau • Jan. 4, 2023

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

To drive trial diversity, one company is bringing them to the patient

For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.

By Karissa Waddick • Dec. 21, 2022

With mpox cases mysteriously dwindling, scientists search for answers

Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.

By Kelly Bilodeau • Dec. 19, 2022